ArticleArchives of gynecology and obstetrics2025
Temporal trends in the prevalence of polycystic ovary syndrome in China from 1990 to 2021, and projections until 2036: a comparison with Japan, Asia, and global level.
Article in Archives of gynecology and obstetrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The crosstalk between polycystic ovary syndrome and Hashimoto thyroiditis: a systematic review and meta-analysis.Frontiers in endocrinology · 2026Pooled it
- Burden of polycystic ovary syndrome in low-and middle-income countries, 1990-2023: results from the global burden of disease study 2023.Tropical medicine and health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe burden of polycystic ovary syndrome is increasing worldwide, which places a heavy burden on society and healthcare systems. This study investigates the independent effects of age, period, and cohort on the polycystic ovary syndrome prevalence from 1990 to 2021 in China, Japan, Asia and World. And then predicts the future burden of polycystic ovary syndrome over the next decade.
methodThe data were collected from the Global Burden of Disease (GBD) 2021 study, and the average annual percent change (AAPC) and relative risks (RRs) analyzed by joinpoint regression and APC-IE model. And this study employed the BAPC model to predict future disease burdens in China and Japan.
resultsIn 2021, there were 533.533*104 (95% CI: 376.054*104, 750.101*104) cases of PCOS in China, accounting for 28.69% of all cases in Asia and 14.56% globally. The ASPR of PCOS in China increased from 1990 to 2021, with an AAPC of 2.01 (95% CI: 1.99, 2.03), which was significantly higher than that of Japan (0.21; 95% CI: 0.20, 0.22), Asia (1.30; 95% CI: 1.28, 1.31) and the global average (0.81; 95% CI: 0.80, 0.82). The age-period-cohort analyses revealed that the relative risk (RR) of polycystic ovary syndrome increased with age, peaking at 20-24 years in Chinese women (RR = 1.591) and Japan women (RR = 1.64). And Japan showed a slight increase in the 35-39 age group (RR = 1.583). The period effect of polycystic ovary syndrome showed a consistent upward trend in China, Japan, Asia, and globally. And China experienced the most substantial increase from 1992-1996 (RR = 0.701) to 2017-2021 (RR = 1.271). The cohort effect of PCOS demonstrated a declining trend across regions, but China and Asia experienced an incline from 2002-2006 to 2007-2011 birth cohort. By 2036, the ASPR of PCOS in China is projected to increase by 27% from 2021, reaching 1961.45/100,000.
conclusionsThe prevalence of the PCOS in China has increased significantly over the past three decades. The age group with a high prevalence of polycystic ovary syndrome among Chinese women is 20-25 years old. And women in the new birth cohort are more likely to develop polycystic ovary syndrome. It is imperative that the government standardize the diagnosis and treatment of polycystic ovary syndrome and provide health education to the women.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.